Eli Lilly will partner with ImmuNext to study and develop a preclinical novel potential target for autoimmune disease treatments, the companies said, through an up-to-$595 million collaboration that is the phama giant’s second autoimmune-focused partnership launched in the past three months. Jay Rothstein, CSO at ImmuNext, described the target in a statement as “a first-in-pathway […]
The post Lilly, ImmuNext Launch Up-to-$595M Autoimmune Disease Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Lilly, ImmuNext Launch Up-to-$595M Autoimmune Disease Collaboration